Sage Therapeutics (SAGE)
(Real Time Quote from BATS)
$12.42 USD
+0.13 (1.06%)
Updated Jul 22, 2024 02:18 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Income Statements
Fiscal Year end for Sage Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 86 | 8 | 6 | 1,114 | 7 |
Cost Of Goods | 2 | 1 | 1 | 1 | 0 |
Gross Profit | 84 | 7 | 6 | 1,114 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 664 | 554 | 467 | 517 | 715 |
Income After Depreciation & Amortization | -580 | -547 | -461 | 596 | -708 |
Non-Operating Income | 38 | 14 | 3 | 10 | 28 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -541 | -533 | -458 | 606 | -680 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -541 | -533 | -458 | 606 | -680 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -541 | -533 | -458 | 606 | -680 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -585 | -540 | -444 | 600 | -713 |
Depreciation & Amortization (Cash Flow) | -5 | 7 | 17 | 4 | -5 |
Income After Depreciation & Amortization | -580 | -547 | -461 | 596 | -708 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 59.84 | 59.31 | 58.67 | 53.00 | 50.83 |
Diluted EPS Before Non-Recurring Items | -8.49 | -8.98 | -7.80 | -9.47 | -13.38 |
Diluted Net EPS (GAAP) | -9.05 | -8.98 | -7.80 | 11.43 | -13.38 |
Fiscal Year end for Sage Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 7.90 | 77.97 | 2.72 | 2.47 |
Cost Of Goods | NA | 1.27 | 0.82 | 0.91 | 0.21 |
Gross Profit | NA | 6.63 | 77.15 | 1.81 | 2.27 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 124.30 | 119.23 | 213.66 | 172.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -117.67 | -42.08 | -211.85 | -170.46 |
Non-Operating Income | NA | 9.19 | 9.37 | 10.22 | 10.13 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -108.48 | -32.71 | -201.63 | -160.33 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -108.48 | -32.71 | -201.63 | -160.33 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -108.48 | -32.71 | -201.63 | -160.33 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 60.14 | 59.99 | 59.91 | 59.77 |
Diluted EPS Before Non-Recurring Items | NA | -1.80 | -0.55 | -2.81 | -2.68 |
Diluted Net EPS (GAAP) | NA | -1.80 | -0.54 | -3.37 | -2.68 |